Loading
CEACAM5 is the cell-surface form of the tumour marker CEA, high on many lung and bowel cancers. Tusamitamab ravtansine was tested in CEACAM5-high lung cancer but failed its phase 3 and no approval exists.
The CARMEN-LC03 trial (NCT04154956) selected non-squamous NSCLC with CEACAM5 expression at 2+ intensity in 50 percent or more of tumour cells by IHC; it did not meet its endpoints and development stopped in 2023. Newer CEACAM5 ADCs and bispecifics are in early trials with similar IHC gates. No label names CEACAM5.
In plain words · The classic 'CEA' tumour marker measured in blood, also present on the cell surface where ADCs can reach it.
CEACAM5 staining is not a routine test and no approved drug depends on it; the one late-stage antibody-drug conjugate aimed at it did not succeed. Trials of newer CEACAM5 drugs may use the stain to select patients.
Written only from the label or guideline text cited on this page. Not medical advice; your own report and the reading your team gives it come first.
The label names the antigen in the drug's description but does not require it to be measured before treatment; no approval threshold exists for this readout.
“CARMEN-LC03: tusamitamab ravtansine versus docetaxel in CEACAM5-positive non-squamous NSCLC”
ClinicalTrials.gov NCT04154956 (CARMEN-LC03)No approval uses this readout as a threshold. It is defined by CARMEN-LC03 (NCT04154956): CEACAM5 IHC 2+ in >= 50% of tumour cells.
Matched on the name and aliases of the readout in the title, setting and summary of each trial; a match is a mention, not proof the readout was an entry criterion.
Shares TROP2 expression and the tags biomarker, surface-antigen, no-threshold.
Shares Non-small-cell lung cancer and the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.